Phase II
Spark Therapeutics, with its partner Pfizer, published interim data from its Phase I/II clinical trial of a gene therapy for hemophilia B in The New England Journal of Medicine.
Shares of Sage have shot up more than 75 percent this morning as a result of the impressive data.
The results demonstrate that the combination of BL-8040 with HiDAC in this difficult-to-treat patient population significantly improved overall survival, compared with historical data of HiDAC monotherapy.
The patients who were transfusion dependent and switched from Soliris were forced to switch back to the Alexion drug.
Nobody is interested in slow-growth or no-growth stocks, long term or short term, but everyone’s interested in fast-growing stocks.
With the $63.5B takeover of Monsanto by Bayer taking longer than expected, and a key patent for Xarelto expiring in 2024, Bayer’s execs are finding themselves defending their decisions.
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
While lirilumab was shown to be well-tolerated, it did not demonstrate efficacy in treating that patient population.
Regeneron indicated that because of disappointing results for two Phase II trials, it was ending its development of angiopoietin2 antibody nesvacumab as an addition to Eylea.
Researchers are making great headway against cancer, even though it’s currently still the second-leading cause of death in the U.S.
PRESS RELEASES